1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial
    Meeting Abstract

    Motzer, R. J.; Russo, P.; Grünwald, V.; Tomita, Y.; Barthélémy, P.; Goh, J. C.; Cutuli, H. J.; Simsek, B.; Spiridigliozzi, J.; Chudnovsky, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial
    Meeting Abstract

    Economides, M. P.; Milowsky, M. I.; O'Donnell, P. H.; Alva, A. S.; Kollmeier, M.; Rose, T. L.; Pitroda, S. P.; Rosenberg, J. E.; Hochman, T.; Goldberg, J. D.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study
    Meeting Abstract

    Lee, C. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent Duran, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial
    Meeting Abstract

    Cella, D.; Choueiri, T. K.; Blum, S. I.; Ejzykowicz, F.; Wallace, J.; Zhang, J.; Simsek, B.; Ivanescu, C.; Motzer, R. J.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Merchan, J. R.; Goh, J. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up
    Meeting Abstract

    Gupta, S.; Rosenberg, J. E.; McKay, R. R.; Flaig, T. W.; Petrylak, D. P.; Hoimes, C. J.; Friedlander, T. W.; Bilen, M. A.; Srinivas, S.; Burgess, E. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS
    Meeting Abstract

    Cytryn, S. L.; Solit, D. B.; Walch, H. S.; Chatila, W. K.; Maron, S. B.; Vakiani, E.; Brannon, A. R.; Ladanyi, M.; Schultz, N.; Berger, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genomic characterization of FGFR-altered solid tumors using a clinically annotated pan-cancer repository
    Meeting Abstract

    Choudhury, N. J.; Harada, G.; Whiting, K.; Shen, R.; Yang, S. R.; Solit, D. B.; Berger, M. F.; Dinapoli, S.; Abou-Alfa, G. K.; Iyer, G.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis
    Meeting Abstract

    Pant, S.; Schuler, M. H.; Iyer, G.; Witt, O.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; Welsh, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save